We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alaunos Therapeutics Inc (TCRT) NPV

Sell:$1.88 Buy:$2.32 Change: $0.0739 (3.77%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.88
Buy:$2.32
Change: $0.0739 (3.77%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.88
Buy:$2.32
Change: $0.0739 (3.77%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Contact details

Address:
2617 Bissonnet St, Suite 225
HOUSTON
77005
United States
Telephone:
+1 (617) 2591970
Website:
https://alaunos.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TCRT
ISIN:
US98973P3091
Market cap:
$3.14 million
Shares in issue:
1.60 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Dale Hogue
    Interim Chief Executive Officer, Director
  • Ferdinand Groenewald
    Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.